BackBio-Techne Overview
Bio-Techne Corp

Bio-Techne Discounted Cash Flow

Is TECH undervalued? Intrinsic value estimate stands at $22.

Get informed when a big investor buys or sells

+ Follow

Fair Value

$21.61

Current Fair Value

$21.61
↓ 70.3% Downside

Overvalued by 70.3% based on the discounted cash flow analysis.

Average Upside/Downside (Comparison Companies)

Loading

Fair Value vs. Stock Price History

Loading

Upside/Downside History

Loading

Upside/Downside Comparison

Loading

Bio-Techne (TECH) FAQ

As of the most recent data, TECH shows a DCF fair value of $22. Scroll down for historical charts and peer comparison views.

Bio-Techne's DCF reading of $22 (70.3% overvalued) is a model output, not a certainty. Small changes in long-term growth or the discount rate can move fair value a lot. Treat the number as a structured starting point, then verify whether Bio-Techne's recent cash-flow history supports the assumptions.

Besides this discounted cash flow page, Stockcircle has Bio-Techne's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect DCF fair value (currently $22) with ownership activity and broader fundamentals.

Bio-Techne's DCF fair value is $22; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.